UYG
Get informed when a big investor buys or sells
+ Follow| Market cap | $29.76 Billion |
|---|---|
| Enterprise Value | $29.59 Billion |
| Dividend Yield | $10.69 (12.58%) |
| Earnings per Share | $- |
| Beta | 1.65 |
| Outstanding Shares | - |
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2265.7 |
| Enterprise Value to EBIT | -393.61 |
| Enterprise Value to Net Income | -420 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2597▲ 26.89% |
|---|---|
| Total Calls | 15,400▼ 29.36% |
| Total Puts | 19,400▼ 10.19% |
Holdings and activity of institutional investors.
| Ownership % | 3.59%▼ 0.03% |
|---|---|
| Total Invested | $22.11M▼ 30.35% |
| Investors Holding | 65▼ 14.00% |
No data
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...